Eculizumab

BNF:: 9.1.3
Status:: Do Not Prescribe (DNP), Red
Decision Date:: February 2015

Comments

RED: NICE HST1: for treating atypical haemolytic uraemic syndrome.

DO NOT PRESCRIBE (DNP)⁶: NICE TA636 - refractory myasthenia gravis (terminated appraisal) (Decision date - July 2020)

DO NOT PRESCRIBE (DNP): NICE TA647 - relapsing neuromyelitis optica (terminated appraisal) (Decision date - October 2020)

Black Drug Classifications

6: Have NICE guidance that recommends they should not be used

Red Drug Classifications

1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)